Gene and Cell Therapy for Sarcomas: A Review
Cancers · 27.03.2025 · 17 (7) · 1125
DOI: 10.3390/cancers17071125 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 27.03.2025. Verfasst von Sant P Chawla und 7 weiteren Autor:innen. Beteiligte Einrichtung: Sarcoma Oncology Center/Cancer Center of Southern California, Santa Monica, CA 90403, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The heterogeneity of sarcomas and resulting distinct sub-type specific characteristics, their high recurrence rates, and tendency for distant metastasis, continue to present significant challenges to providing optimal treatments.
Objective
To provide a comprehensive review of current literature and clinical trials in gene and cell therapies for sarcomas.
Methods
A comprehensive literature search was conducted utilizing the following databases: PubMed, Medline, Google Scholar and clinicaltrials.gov. Search terms included “gene therapy”, “cell therapy”, “NK cell therapy, “CAR-T therapy”, “virotherapy”, “sarcoma”, “gene therapy”, and “solid tumors”. Additional sources were identified through manual searching for references of relevant studies. No language restrictions were set. The NCT number, study status, condition, and phase were noted for clinical trials.
Results
There are only three gene and cell therapies for sarcomas that have been approved by a federal regulatory agency. Rexin-G: the first tumor-targeted gene therapy vector designed to target all advanced solid malignancies, including chemo-refractory osteosarcomas and soft tissue sarcomas, was approved by the Philippine FDA in 2007. Gendicine was the first oncolytic virus approved for intratumoral delivery in China in 2003. Afami-cel, an innovative chimeric antigen receptor (CAR) T cell therapy, was approved for synovial sarcoma in the United States in 2024. Other promising therapies are discussed in the text.
Conclusions
The future of gene and cell therapy for sarcomas holds great promise, as research moves to late-stage clinical development. The integration of gene and cell therapies into standard sarcoma treatment protocols has the potential to significantly improve the quality of life and outcomes for patients with this rare and challenging group of cancers.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Sarcoma Oncology Center/Cancer Center of Southern California, Santa Monica, CA 90403, USA.
- Aveni Foundation, Santa Monica, CA 90403, USA.
- NKGen Biotech, Inc., Santa Ana, CA 92705, USA.
- Delta Next-Gene, LLC, Santa Monica, CA 90405, USA.
Zitieren
APA
Chawla, S. P., Pang, S. S., Jain, D., Jeffrey, S., Chawla, N. S., Song, P. Y., Hall, F. L., & Gordon, E. M. (2025). Gene and Cell Therapy for Sarcomas: A Review. Cancers, 17(7), 1125. https://doi.org/10.3390/cancers17071125
Vancouver
Chawla SP, Pang SS, Jain D, Jeffrey S, Chawla NS, Song PY, et al. Gene and Cell Therapy for Sarcomas: A Review. Cancers. 2025;17(7):1125. doi:10.3390/cancers17071125
BibTeX
@article{Chawla2025,
author = {Chawla, Sant P and Pang, Skyler S and Jain, Darshit and Jeffrey, Samantha and Chawla, Neal S and Song, Paul Y and Hall, Frederick L and Gordon, Erlinda M},
title = {Gene and Cell Therapy for Sarcomas: A Review},
journal = {Cancers},
year = {2025},
volume = {17},
number = {7},
pages = {1125},
doi = {10.3390/cancers17071125}
}
EUVIMED